Clinical trial · Interventional
cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas
Evaluation of Circulating DNA as a Biomarker of Residual Disease After Chemoradiotherapy for Locally Advanced Head and Necksquamous Cell Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 12, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260912-000001
Summary
Brief summary (as posted)
The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma. The main question it aims to answer is : \- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological). Participants will : * be included in the main study (Neck-TAR) * have a blood sample 1 and 3-month after the end of treatment
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced Head and Neck Carcinoma | Head and Neck Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood sampling | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- cDNA detection
- interventionNames
- Biological: blood sampling
Primary outcomes (1)
- measure
- cDNA detection and objective response 3 months after the end of chemoradiotherapy
- timeFrame
- 3 months after chemoradiotherapy
- description
- The detection or non detection of cDNA after treatment will be compared with the objective response (complete response versus progression/stability/partial response)
Secondary outcomes (6)
- measure
- cDNA detection and objective response one month after the end of chemoradiotherapy
- timeFrame
- 1 month after the end of chemoradiotherapy
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Selection Criteria: * Patient included in NeckTAR study * Written informed consent signed for NeckTAR-IN study * Affiliation to the French social security system
References
Publications (1)
- BACKGROUNDGinzac A, Ventelou L, Ferreira MC, Canetti L, Biau J, Molnar I, Ponelle-Chachuat F, Philippe S, Saroul N, Pham-Dang N, Durando X, Bernadach M. Prospective multicentre study evaluating ctDNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: NeckTAR-IN protocol. BMJ Open. 2026 Aug 7;16(8):e118532. doi: 10.1136/bmjopen-2026-118532. PMID 42567634